Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
05 août 2019 07h30 HE
|
Arbutus Biopharma Corporation
- Appointed William Collier, with decades of leadership experience in antivirals, President & CEO - Announced preliminary Phase 1a/1b clinical trial results demonstrating that AB-506 is a potent...
Arbutus Sells Part of its ONPATTRO™ (patisiran) Royalty Interest to OMERS
02 juil. 2019 16h01 HE
|
Arbutus Biopharma Corporation
- Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant downstream economics - Runway extended with non-dilutive capital WARMINSTER, Pa., July 02,...
Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D.
17 juin 2019 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., June 17, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the...
Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update
06 mai 2019 16h01 HE
|
Arbutus Biopharma Corporation
Top-line safety and efficacy results from an interim analysis of the initial Phase 1a/1b clinical trial of AB-506, a proprietary oral capsid inhibitor, expected in July 2019 Conference Call and...
Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives
07 mars 2019 16h01 HE
|
Arbutus Biopharma Corporation
- Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg - Ongoing analyses of AB-452, a novel orally-available...
Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors
26 nov. 2018 16h41 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update
07 nov. 2018 16h01 HE
|
Arbutus Biopharma Corporation
- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial - ONPATTRO™ (patisiran) approved by the U.S. Food and Drug Administration (FDA) and the...
Arbutus Names New Members to its Board of Directors
22 oct. 2018 08h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that James...
Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer
09 oct. 2018 08h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a change...
M2 Compliance to Sponsor MicroCap Conference in New York at Essex House
29 sept. 2018 12h42 HE
|
M2 Compliance
NEW YORK, NY, Sept. 29, 2018 (GLOBE NEWSWIRE) -- M2 Compliance ("M2") (www.m2compliance.com), a world-leading SEC registered filing agent and full-service financial printer, announced it would be...